Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib

The dual SRC/ABL1 tyrosine kinase inhibitor bosutinib is indicated for adults with Ph+ chronic myeloid leukaemia (CML) resistant/intolerant to prior therapy. This analysis of an ongoing phase 1/2 study (NCT00261846) assessed effects of baseline patient characteristics on long‐term efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Brümmendorf, Tim H., Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Kim, Dong‐Wook, Schafhausen, Philippe, Conlan, Maureen G., Shapiro, Mark, Turnbull, Kathleen, Leip, Eric, Gambacorti‐Passerini, Carlo, Lipton, Jeff H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737299/
https://www.ncbi.nlm.nih.gov/pubmed/26537529
http://dx.doi.org/10.1111/bjh.13801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737299/
https://www.ncbi.nlm.nih.gov/pubmed/26537529
http://dx.doi.org/10.1111/bjh.13801

Ejemplares similares